# Reasons For PMTA Deficiencies | Accorto Regulatory Solutions

https://accortoreg.com/insights/pmta-deficiencies-causes-solutions

> Advisory content from a regulatory consultancy: useful for practical guidance and examples but should be treated as firm-specific interpretation and not as a substitute for direct FDA guidance or legal advice. Attribute regulatory claims to Accorto and verify regulatory or legal details against primary sources (FDA/21 CFR).

## Summary

This Accorto article explains why the FDA issues deficiency letters during substantive review of Premarket Tobacco Product Applications (PMTAs), lists the most common ENDS-related deficiencies Accorto observes (behavioral science studies, aerosol characterization, inhalation toxicology, and manufacturing/quality documentation), and provides recommended response structure and practical considerations for applicants.

## Audience

PMTA applicants and regulatory professionals (manufacturers and submission teams)

## Prompts this page answers

- What are the most common reasons the FDA issues deficiency letters for PMTAs?
- How should I structure a response to an FDA PMTA deficiency letter?
- Why is aerosol testing needed for ENDS PMTAs when e-liquid chemistry is available?
- What behavioral studies does the FDA expect in a PMTA (TPPI vs actual-use)?
- What are typical manufacturing and quality documentation gaps that cause PMTA deficiencies?

## Purpose

To inform and advise PMTA applicants and regulatory stakeholders about common PMTA deficiencies, how deficiency letters function, and how to prepare responses or prevent deficiencies.

## Highlights

- Deficiency letters are issued during substantive application review and place the PMTA on hold pending response (commonly a 90-day window).
- Accorto commonly sees gaps in behavioral science evidence (TPPI and actual-use studies) when FDA issues deficiencies.
- E-liquid analytical chemistry without aerosol characterization is a frequent deficiency for ENDS PMTAs because aerosol testing is needed to assess inhalation exposure and HPHCs.
- Insufficient inhalation-relevant toxicology and gaps in manufacturing/quality documentation are recurring causes of deficiencies.
- The article recommends a structured response format: restate the issue and provide requested data, justification that the issue does not affect the decision, or acceptable alternative information; include identical deficiency numbering and organization aids (TOC, figures/tables).

## How to cite

Credit Accorto Regulatory Solutions and link to https://accortoreg.com/insights/pmta-deficiencies-causes-solutions.

## Publisher

**Accorto Regulatory Solutions** — Regulatory consulting firm (Accorto Regulatory Solutions) — shown in the site footer and navigation as the page publisher.

## Topics

- PMTA deficiencies
- FDA PMTA review
- ENDS aerosol testing
- TPPI studies
- inhalation toxicology
- manufacturing quality documentation
- Appropriate for the Protection of the Public Health (APPH)

## Key entities

- **U.S. Food and Drug Administration** (organization): Federal agency referenced as issuer of deficiency letters and source of PMTA guidance. — https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/premarket-tobacco-product-applications
- **Premarket Tobacco Product Application (PMTA)** (other): Regulatory submission type discussed throughout the article. — https://accortoreg.com/regulatory-solutions/u-s-pmta/
- **Appropriate for the Protection of the Public Health (APPH)** (other): Regulatory standard FDA uses to evaluate PMTAs; discussed as the decision criterion.
- **Tobacco Product Perception and Intention (TPPI)** (other): Type of behavioral study identified as commonly deficient when absent or non-product-specific.
- **Harmful and Potentially Harmful Constituents (HPHCs)** (other): FDA list used as a starting point for targeted aerosol testing analytes. — https://www.fda.gov/tobacco-products/products-ingredients-components/harmful-and-potentially-harmful-constituents-hphcs
- **Austin Tyner** (person): Author (Document Specialist) of the article, listed in the byline.
- **Valerie Schwartz** (person): Clinical reviewer (Regulatory Specialist I) credited with clinical review in the byline.
- **Accorto Regulatory Solutions** (organization): Publisher and consulting firm providing regulatory services (site owner). — https://accortoreg.com/

## Metadata

- Type: article
- Published: 2026-08-25T00:00:00Z